`
`minimitimflgfddiyjmfiii
`
`l
`AstraZeneca Exhibit 2044 p.
`lnnoPhanna Licensing LLC‘ v. AstraZeneca AB IPR20l7-00904
`Fresenius—Kabi USA LLC v. AstraZeneC-a AB [PR2017-01910
`
`

`

`IFH
`
`INNOVATIVE RESEARCH OF AMERICA
`
`— M
`
`ost scientists agree that the three essential parameters in the success of a biomedical
`experiment are:
`
`A. The scientific problem formulated in a defined question.
`
`B. The laboratory animal, healthy and untraumatized.
`
`C. The process of active product delivery; the most problematic variable of all three!
`
`For a third of a century, Innovative Research of America has assumed the leadership role
`
`in improved time release technology. The main mission is to standardize the technology of
`
`drug delivery. Our proven Time Release Hormone and Drug Pellets help investigators take
`
`charge of product delivery and expand their abilities to do meaningful and reproducible
`
`research.
`
`ADVANTAGES OF THE PELLET DELIVERY SYSTEM
`
`- a ready—toadminister pellet for a simple subcutaneous implantation
`
`° a convenient long—term controlled.prioduCt.relc-:'ase inlaborator'y animal's '
`
`' a better method toaVOid the*peakand valley effectsproducedby conventional dehvery
`methods.
`I
`.
`.
`_
`.
`_
`.
`_
`..
`_
`
`_' anew system to extend the producti'life againstspontaneousandhost—relatedbl‘eakdown2
`
`L1 shering In The Age Of Innovative Research
`
`- a'depe‘ndable way to minimize the.experi1nerital variable-sif- '_
`
`_
`
`Iii-i.-
`
`ii
`
`I
`
`I
`
`I
`
`_- a mere reliable approach for prodHCtiv'e and reproducible" re'sea-rch,.'_ '
`
`AstraZeneca Exhibit 2044 p. 2
`
`

`

`HORMONE AND DRUG PELLETS FOR BIOMEDICAL RESEARCH
`
`—
`
`Since it is not easy to administer drugs and hormones orally to research animals.
`
`several delivery methods have been devised as alternatives. However, most scientists
`
`continue to labor with unreliable injectables to conduct their research.
`
`Because of this inadequacy. biomedical research is as confusing as it is challenging
`
`and as frustrating as it is creative. The Options of scientists to address scientific questions
`
`are not only dependent, but are also limited by the process of active product delivery.
`
`Traditionally, product delivery into the experimental animal has been the procedure most
`
`subject to variables and the most difficult to standardize effectively. The very process
`
`of having to accurately administer drugs to experimental animals can become a logistic
`
`nightmare for scientists.
`
`CHANGING THE TIME COURSE OF DRUG DELIVERY
`
`We Tell Tune-Release Pellets What Time II ls
`
`AstraZeneca Exhibit 2044 p. 3
`
`

`

`Find a Product in this Catalog .......................................................... 5
`
`Ordering Information I General Policy &Terms ............... 6, 7, 44, 84
`
`Sales of Anabolic Steroids ............................................................... 8
`
`Category Index ............................................................................ 10-15
`
`Alkaloids
`Amino Acids
`Androgens
`Antibiotics
`Anti-Inflammatory Agents
`Anti-Neoplastics
`Catecholamines
`
`Corticoids and Diuretics
`
`Estrogens
`Fatty Acids
`Nuoleotide Related Products
`Progestins
`Prostaglandins
`Thyroids
`Vitamins
`
`RA TABLE OF CONTENTS
`
`
`
`Placebo Pellets tniormatmIi .1 Friar-3:- 5C!“"dji|‘“. .
`
`_.
`
`.-
`
`Alphabetical Product Listing ..................................................... 21 -42
`
`Stock Pellet Price Schedules ..................................................... 45-71
`
`Pellets for lmmuno-Deficient Mice
`
`17B-Estradiol lTamoxifen & Sample References ..................... 73-77
`
`Androgens I Anti-Androgens & Sample References ............... 78-80
`
`Trochar & Recommended Implantation Procedure ............... 81, 123
`
`Doxycycline &Tetracycline Pellets in Mice .............................. 85-86
`
`Hormone + Hormone Pellets ..................................................... 89-92
`
`Custom Pellets .......................................................................... 93-108
`
`Selected References ............................................................... 109-122
`
`Order Forms .............................................................. Back of Catalo .
`
`Patents ................................................................... Inside Back Cover
`
`*Forfirrther assistance, view our website at:
`wuwjrmovnsrchcom
`
`We Add Time To Your Day
`
`AstraZeneca Exhibit 2044 p. 4
`
`

`

`PRODUCT DESIGN AND FEATURES
`
`
`
`The Pellet Implantation Methodology provides solutions to:
`
`.. consistency in timing repeated product administrations.
`
`controlling the amount of product administered.
`
`.. stability of the product preparation.
`
`.. safety of the experimenter.
`
`.. neurophysiological trauma to the animal from excessive handling.
`
`.. freeing valuable research time.
`
`eliminating unnecessary and unstimulating laboratory practices.
`
`Scientists from several research disciplines have documented in scientific literature that
`
`our Pellet Delivery System is effective, consistent, reproducible, economical, reliable, and
`
`safe for the animal. See Selected References on pages 109-122.
`
`Only Time Release l-3ttllt'ls' Really Korm- Whnt Time It ls
`
`AstraZeneca Exhibit 2044 p. 5
`
`

`

`PRODUCT SPECIFICATIONS
`
`—
`
`AVAILABLE SHAPES AND SIZES
`
`Stock pellets are round and range in diameter from 11'8" (3 mm) to [12"(125 cm) depending on the
`dose and the release rate. Our Custom Pellets Department will also design various pellet shapes and
`smaller sizes (Page 94) to meet your research needs. Please refer to the Custom Pellets section on pages
`93-108.
`
`AVAILABLE DOSAGES
`
`Most of the stock products in this catalog are available in 20 different dosages ranging from 1 inicrogram
`(0.001 mg) per pellet up to 200 milligrams (200 mg) per pellet within the specified release rate. Doses of
`pellets listed in this catalog reflect the total amount of net active product released over the indicated
`period of time.
`
`AVAILABLE RELEASE RATES
`
`Stock products are designed to release continuously for 21 days, 60 days. or 90 days. Please refer to our
`Custom Pellets section on pages 93- 108 for other release rates tailored for the duration of the experiment.
`
`AVAILABLE PRODUCTS
`
`In our continuing quest to make available new stock items that are particularly in demand, we have added
`several products to the original categories. In addition to the listed pelletized products, Innovative
`Research of America has an efficient Custom Pellets Department to prepare products that are not available
`as stock items.
`
`SELECTED REFERENCES
`
`A sample of publications that employed our delivery system in a broad spectrum of products can be found
`on pages 109-122.
`
`Consistent Dose-Dependent. Release
`
`AstraZeneca Exhibit 2044 p. 6
`
`

`

`FINDING A PRODUCT IN THIS CATALOG
`
`The PRODUCTS in this catalog are arranged in ALPHABETICAL ORDER and are identified by
`a CATALOG NUMBER and 21 PRICE SCHEDULE with a PAGE NUMBER.
`
`The catalog number and price schedule reflect a release rate of 2] days, 60 days. or 90 days.
`
`To illustrate. with l7B-Estradiol as an example:
`
`EXAMPLE
`
`Product
`
`21-Day Release
`Catalog
`Price Schedule!
`Number
`Page Number
`
`60- Day Release
`Catalog
`Price Schedule!
`Number
`Page Number
`
`90- Day Release
`Catalog
`Price Schedulerf
`Number
`Page Number
`
` 171?:- Estradiol
`
`NE- 12]
`
`8-9050
`
`E 121
`
`3212'48
`
`SE— 121
`
`13—60149
`
`The above example indicates that I7B*Estradiol is available in three release forms each having a
`
`different catalog number and price code, i.e.
`
`E - I2! is a 2l~day release form with a price code of 8-21. found on page 48.
`
`SE - 12! is a 60-day release form with a price code of 3-60. found on page 49.
`
`t
`
`NE - 121 is a 90-day release form with a price code of 8-90, found on page 50.
`
`The PAGE NUMBER next to the PRICE SCHEDULE indicates the page where the actual price
`
`for the product appears-
`
`When ordering please. use the PRODUCT NAME. CATALOG NUMBER. RELEASE
`
`RATE and DOSE. Most products are available in 20 different dosages. Products are sold in
`
`Lots of 25, 50, 100. and 200 pellets. Please indicate the quantity of pellets being ordered.
`
`Beginning on Page 10 we have grouped some of our catalog items in related categories
`
`alphabetically. We hope the listing will help in noting items of potential interest.
`
`"lime-Release Pellets... Always On Time
`
`AstraZeneca Exhibit 2044 p. 7
`
`

`

`
`
`~ Mail
`
`0 Internet I E-Mail
`
`Innovative Research of America, Inc.
`
`http://WWW-innovrsrch-com (website)
`
`2 North Tarniami Trail
`
`pellets@innovrsrch.com (e-mail']
`
`Suite 404
`
`Sarasota, Florida 34236 USA
`
`' Phone
`
`(941) 365-1406
`
`(941) 365-1506
`(800) 421-8 171 (USA/Canada)
`
`0 Fax
`(941) 365—1703
`
`(941) 365-1803
`
`(800) 643-4345 (USAfCanada)
`
`(800) 648-6030 (USA/Canada)
`
`IRA‘s website features our company profile,
`the latest product technology and on-line ordering.
`
`- AMERICAN EXPRESS.
` VISAAND MASTERCARD ACCEPTED.
`
`In: Purchase Order Forms are in the back of the
`catalog.
`
`Custom Pellets Information Form on page 95.
`
`THE DiFFERENCE is
`cowsrerNcr AND umFottmm’.
`
`33mm1800 Second 5L. Suite 100
`Sarasota. Florida 34236
`
`Bank Wire Payment Information
`Payment via bank wire sitouid be directed as inflows:
`
`Routing 6‘ (ABA) 263191337
`Electronic Transfers # 263191387
`
`In favor of:
`Innovative Research of America
`
`Swift Code: BRBTUS33
`
`2 North Tamiami Trail
`Suite 404
`
`Sarasota, FL 34236
`
`Checking Account: #0000147316154
`
`Ushering In The Age Of Ir1nm--'ziti\-'e Research
`
`AstraZeneca Exhibit 2044 p. 8
`
`

`

`GENERAL POLICY AND TERMS
`
`POL [C Y
`
`7&5": r:
`
`L:
`
`_\
`_
`'33::
`0% 0:: .
`
`'.
`
`.
`
`AstraZeneca Exhibit 2044 p. 9
`
`

`

`SALE OF CONTROLLED ANABOLIC STEROIDS
`
`within the United States
`—
`
`(Telephone orders will not be accepted - orders 8.: copy of DEA license may be mailed or faxed)
`
`Before we can prepare any orders of Anabolic Steroid Pellets, the Drug
`
`Enforcement Administration (DEA) requires us to obtain:
`
`1. A valid photocopy of the investigator’s DEA Registration
`
`containing Schedule 3N.
`
`2. A written Purchase Order showing the investigator’s DEA
`
`Registration Number and proper shipping address
`
`CONTACT INNOVATIVE RESEARCH OF AMERICA
`
`BY PHONE. MAIL, FAX OR E-MAIL
`
`FOR MORE ORDERING INFORMATION - SEE PAGE 6
`
`SALE OF CONTROLLED ANABOLIC STEROIDS
`
`outside the United States (International)
`—
`
`WE NO LONGER SHIP ANABOLIC STEROIDS
`
`outside the United States (International)
`
`DEA Controlled Anabolic Steroids
`
`Androstenediol
`
`l9—Nortestosterone l7-Decanoate
`
`Androstenedione
`
`l9—Nortestosterone l?-Dipropionate
`
`SOL-Diliydrotestosterone
`
`Fluoxymesterone
`
`Mesterolone
`
`Mesterone
`
`Methandriol
`
`Methandriol Dipropionate
`
`Stanozoiol
`
`Testosterone
`
`Testosterone Acetate
`
`Testosterone Benzoate
`
`Testosterone Cypionate
`
`Testosterone Enanthate
`
`19-Nortestosterone
`
`Testosterone l7ts-Hemisuccinate
`
`,1.
`
`Testosterone Propionate
`
`Time Release Pellets Always On Time
`
`AstraZeneca Exhibit 2044 p. 10
`
`

`

`U1
`
`'4
`
`and specific references.
`
`See pages 73—80 regarding
`Hormone/Anti-Hormone products
`for Immune—Deficient Mice
`
`Your Research Time Is Under Your Control
`
`AstraZeneca Exhibit 2044 p.
`
`l I
`
`

`

`CATEGORY INDEX
`
`5:
`
`On the following 6 pages, we have grouped some of our Catalog items in related categories.
`Hopefully this listing will help in noting items of potential interest.
`
`
`
`il
`
`10
`
`AstraZeneca Exhibit 2044 p. 12
`
`

`

`We Add A Link Timc To Your Day
`
`.x\N'l“I—INFLA M MATORY AGENTS
`
`AstraZeneca Exhibit 2044 n.13
`
`

`

`
`
` (ii-“X'I‘ECH OLA MINES AN D RELATED PRODUCTS
`
`12
`
`It‘s Time For Clean: Comislem Results
`
`AstraZeneca Exhibit 2044 a. 14
`
`

`

`CATEGORY INDEX (continued)
`
`When Reliability Counts.
`
`AstraZeneca Exhibit 2044 n.15
`
`

`

`CATEGORY INDEX (continued)
`
`
`
`"firggfiehblbné
`Proggstei’ong .-
`
`Use Time To Your Advantage
`
`AstraZeneca Exhibit 2044 p. 16
`
`_
`
`'
`
`"
`
`

`

`CATEGORY INDEX (continued)
`
`_ ophbléstérdl '(P'rciéitarnin‘b-a) -'
`étérdl '[ffr'a'vit‘amin D]
`'
`
`.
`H,
`:1
`.fl.
`aath
`
`Consistent Results With Consistent Release
`
`vi't'a- n-H Ha? tar-i
`___'.—--..visa'mi'n.sKH'f.--'.
`-
`3 .'...'3Vitainin Kg‘lfiéfiadibnél
`
`..
`
`.
`
`_' "-
`
`AstraZeneca Exhibit 2044 p. 17
`
`

`

`i'
`
`F
`
`ADVANTAGES OF OUR MDD PELLET SYSTEM
`
`. Saves time
`
`o Ready-to-implant
`
`o
`
`lnsures controlled product release over time
`
`o Avoids “peak and valley” effects
`
`, Guarantees consistent product preparation
`
`9 Extends product life against spontaneous breakdown
`
`o Extends product life against host-related breakdown
`
`o Minimizes experimental variables
`
`0
`
`lnsures safety of the researcher
`
`. Reduces neurophysiological trauma to the animal!
`
`no r"cessive handling
`
`. Generates more meaningful and reproducible results
`
`0 Superior to conventional delivery methods
`
`0 Enhances experimental efficiency
`
`. Frees valuable time for creative research
`
`0 Saves money
`
`Time-Release. Pellets... Always On Time
`
`AstraZeneca Exhibit 2044 p. 18
`
`

`

` .\blologtcal'._ esultson ...ne
`
`'_._'.: _._ _.L-.__.—';_._.-_._-.£.'__'__' __'.;..
`
`Matching Placebo pellets contain all the components of the hormone or drug pellet except the active
`product itself. The carrier-binder excepients of the matrix include Cholesterol, Lactose, Celluloses,
`Phosphates and Stcarates.
`
`|
`
`Stock Placebo pellets are available in 20 different doses corresponding to those of active product
`pellets. Each dose is offered in either 2] Day, 60 Day, or 90 Day Release form.
`
`Although the matrixcs in Placebo pellets have a different composition for different active products,
`they are all assigned the same catalog number and are offered at the same price schedule.
`
`When inquiring or placing an order, please specify the active product you wish to correspond the
`
`Placebo pellets for. Please see the following examples:
`
`l
`ll
`
`‘
`
`Catalog No.
`
`Description
`
`Dose in mgipcllct
`
`Release in Days
`
`" NC-lll
`
`011]
`
`SC-l ll
`
`Placebo for “Active Product“
`
`Placebo For “Active Product“
`
`rug/pellet
`
`mg!pellet
`
`Placebo for “Active Product“
`
`mg/pellet
`
`';.
`
`21 Day
`
`60 Day
`
`90 Day
`
`I
`
`*ln place of “Active Product” specify the hormone or drug you are utilizing in your study.
`
`The following three pages are universal dose {price schedules in all three release rates (21 Day, 60
`Day, and 90 Day) and are applicable as a matching Placebo for all products in the catalog except
`Special physical size and preparations (page 94) which can be found under the Custom Pellet section
`on pages 93-108.
`
`*Please inquire direcrbv with as {flitrther assistance is required regarding a product ofinterest.
`
`
`
`AstraZeneca Exhibit 2044 p. 19
`
`

`

`AstraZeneca Exhibit 2044 p. 20
`
`
`

`

`PLACEBQ PELLETSELE
`
`
`
`PRICE SCHEDULE
`
`Cat. No. C-1 11
`
`mgfpellet
`
`.661
`
`1
`
`6667
`
`61362
`
`62646
`
`64616
`
`1
`
`6.616
`
`07025
`
`C1135
`
`6.1
`
`6625
`
`6.5
`
`1 .5
`
`2.5
`
`5.6
`
`6667
`
`6667
`
`6667
`
`6667
`
`6667
`
`6667
`
`6667
`
`6667
`
`6667
`
`61362
`
`61362
`
`61362
`
`61362
`
`61362
`
`331362
`
`61362
`
`61362
`
`61362
`
`62646
`
`62646
`
`62646
`
`62646
`
`62646
`
`62646
`
`62646
`
`62646
`
`62646
`
`64616
`
`64616
`
`54616
`
`64616
`
`54616
`
`64616
`
`54616
`
`64616
`
`64816
`
`
`
`7 5
`
`16 6
`
`16.6
`
`25;
`
`35.6
`
`50.0
`
`7566
`
`6762
`
`6762
`
`6762
`
`6767
`
`6767
`
`6767
`
`6767
`
`61376
`
`61376
`
`61376
`
`61366
`
`61366
`
`61366
`
`61366
`
`62674
`
`62674
`
`62674
`
`62674
`
`62674
`
`62674
`
`62674
`
`
`
`64656
`
`64656
`
`6465:
`
`64675
`
`64675
`
`64675
`
`64:75
`
`64645
`
`64645
`
`64664 W
`
`
`
`
`
`
`
`A cmmbination 0f multiple (images in 0116 11:11, far any specified product, is also
`available. PLEASE INQUIRE
`
`Sixty and Ninety 1363' price schedules 676 on the fallawing twe pages.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1T
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`AstraZeneca Exhibit 2044 p. 21
`
`

`

`
`
`PRICE SCHEDULE
`
`
`Cat. NO. 80111
`
`0.010
`
`(1025
`
`0.05
`
`0.1
`
`0.25
`
`0.5
`
`1.5
`
`2.5
`
`5.0
`
`7.5
`
`“113
`
`15.0
`
`25.0
`
`35.0
`
`50.0
`
`7520
`
`106.0
`
`$731
`
`$731
`
`$731
`
`$731
`
`$731
`
`$731
`
`$731
`
`$731
`
`$731
`
`$?38
`
`$738
`
`$732
`
`$744
`
`$744
`
`$744
`
`$744
`
`$782
`
`
`
`
`
`150.13
`
`$2751
`
`$2751
`
`$2751
`
`$2751
`
`$2751
`
`$2751
`
`$2751
`
`$2751
`
`$2751
`
`$2751
`
`$2789
`
`$2782
`
`$2789
`
`$2$04
`
`$2304
`
`$2804
`
`$2884
`
`$2879
`
`$2872
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`$28Q4
`
`
`
`$762
`
`A cambinatign 0f multiple desagas in one 101, for any specified praduct. is also
`avafiabfia PLEASE MQUIRE‘.
`
`
`AstraZeneca Exhibit 2044 p. 22
`
`

`

`
`.___.____
`_._ __ _______';__ _._. _.l
`__ fifi""_ _-_
`_
`I-
`-- —
`-- —f:—_-_--.:E _m. "WT“‘T-rrf' —_ T .. _q_ —"'P""."':\""-".|f"‘“f'."“‘_":—"'-"—'“=""“'—'We _.I
`
`____BLACEBO PELLET
`
`_
`
`~91
`
`PRICE SCHEDULE
`
`
`
`
`
`A combination of multiple dosages in one lot, for any specified product, is also
`available. PLEASE INQUIRE.
`
`
`
`AstraZeneca Exhibit 2044 p. 23
`
`

`

`
`
`F":
`
`..-
`
`O
`
`O
`
`o
`
`.
`
`.
`
`.
`
`_
`
`
`
`TIME RELEASE PELLETS FOR
`
`BIOMEDICAL RESEARCH IN
`
`LABORATORY ANIMALS
`
`Mul’t’i-Stepi-InjectiagszI-éée--Con-tinuous Pain in DRUG DELIVERY
`
`0ne§St_e_p COntinIIOIis Release Pellets Are the Best Alternative
`
`F 0 P
`3
`I H l! {:3 2:?th I V E
`R F S E 3". R {‘H
`
`...
`
`Time Release Pellets
`
`for Biomedical Research from IRA
`DOSE
`
`O)))))))))))))))))))
`
`RELEASE
`
`O))))))))))))))
`O))))))
`
`Our Team at IRA is working
`to meet the responsibility that
`Innovative Science demands
`and Innovative Scientists
`
`deserve.
`
`
`
`AstraZeneca Exhibit 2044 p. 24
`
`

`

`To illustrate with Acetazolamide as an example, please View the following table:
`
`Product Name
`
`2] Day Release
`
`60 Day Release
`
`91} Day Release
`
`Catalog
`Number
`
`Price Schedule!
`Page Number
`
`Acetazolamide
`
`D-lll
`
`C2! ISI
`
`Catalog
`Number
`
`80-!”
`
`Price Schedule!
`Page Number
`
`Catalog
`Number
`
`Pn‘ee Schedule!
`Page Number
`
`C60 ! 52
`
`ND-lll
`
`C90 ! S3
`
`The PRODUCT NAMES in this catalog are arranged in ALPHABETICAL
`ORDER and are identified by their individual CATALOG NUMBERS including a
`PRICE SCHEDULE and corresponding PAGE NUMBER. The catalog number and
`price schedule reflect a release rate of 21 Days, 60 Days, or 90 Days.
`
`Maximum Flexibility
`
`The above example indicates the stock productAcetazolamide is available in three release
`forms each having a different catalog number and price code, i.e.
`
`0-1 I l. is a 2| Day Release form with a price code of GE]. found on page SI.
`
`30-! l l
`
`is :1 6|] Day Release form with a price code of C-fitl, found on page 52.
`
`ND-l 11 is a 90 Day Release form with a price code of 090. found on page 53.
`
`The PAGE N UMBER next to the PRICE SCHEDULE indicates the page where the actual
`price. for the product appears.
`
`When placing an order, please include the PRODUCT NAM E, CA’I‘A LOG N L: M BER. DOSE lN
`MfuPELLET and RELEASE RATE. Most of our products are available in 2|] different doses.
`Products are normally sold in lots of 25, 50, 100, and 200 pellets. Please indicate. the quantity
`of pellets to he ordered.
`
`Beginning on page 10, we have grouped some of our catalog items by related categories
`alphabetically. We hope the listing will help in noting items olpotenlial interest.
`
`*Please inquire directly with as iffi:rther assistance is required regarding a product ofin(crest.
`
`AstraZeoeca Exhibit 2044 p. 25
`
`

`

`
`
`AstraZeneca Exhibit 2044 p. 26
`
`

`

`ALPHABETICAL PRODUCT LISTING
`
`— D
`
`osefPrice Schedules For Matching Placebo Pelleis Appear On Pages 17-19.
`
`)
`I ['(IdUCt
`
`Valuing I'I'it'c Schedule!
`Number Page NumhL-r
`
`Cmulng I'ricc Schedule!
`Numlu-r Page Number
`
`(fuming l’l'icc Schedule!
`Number Page Number
`
`21-Day Release
`
`60-Day Release
`
`90-Day Release
`
`Acebutolol
`
`0-101
`
`B—21!48
`
`B-BOMQ
`
`1113-101
`
`B-90!50
`
`-iZéfiéétéhiidofluo'rerie121MB
`Acetarsone
`
`A102 ““45 ?--”'IA-60!46’9[!
`8-165
`B-21!48
`B-GOMQ
`-'
`
`13-90150
`
`_ D111 02151
`
`_- ~C-60!52 _, _
`Acetazolémide .
`c-102
`B-21!48
`B-BU!49
`Acetooromazine
`' 94212:}
`
`[9921314971 7- "-':.__:}fBi-'6.I0!z:199
`I“???fQ-Aootyowérnitine
`01-212
`B-Z1!48
`B-BOMQ
`N-A-cetyI-L-Cysteine
`' 30-2722;
`if? ”137211495 I 34601491}:
`heofiLL-GIutamine'
`Q-2?3
`3-21.!48
`-
`B-SDMQ
`-- N-Acetylimidazole
`Im-Nfieetylprocalnamlde I-C-106 A21!45~ I A-60!46
`
`I
`
`I
`
`'
`
`'5
`
`I'r'
`
`cisAconitic Acid
`
`11-111
`
`B-21!48
`
`gtrans-Acomtlc Acid
`
`Aconitine
`
`E'momyom D {Dadlnomycin}
`
`Adenosine
`
`11-112
`
`K413
`
`2—110
`
`N411
`
`- 0-21-1151
`
`I
`
`E-21!57
`
`11-21169
`
`C—21!51
`
`..
`
`‘G-‘l'fi‘fi
`
`'
`
`B-21!48_-
`
`-
`
`I-
`
`-
`
`'
`
`-
`
`-_
`
`'
`
`B-BO!49
`
`9.90152-
`
`E-60!58
`
`11950931 'I
`
`0-6052
`
`.
`
`-
`
`-
`
`-
`
`'I-I
`
`9
`
`III
`
`B90150
`
`c90153;:
`
`E-90!59
`
`i 1.191962
`
`C-90!53
`
`-B-‘60!49 . _'
`
`B-MSG:
`
`
`
`@6052" I.
`
`1-1-9995;
`
`-
`
`-
`
`-
`
`~
`
`B-90!50
`
`11.991627
`
`9—9059
`
`390150
`
`($90153:
`
`B90150
`
`' AH99162
`
`B 90:50
`
`A—QOMT
`
`E’fidrenalCortex Acetone Powder
`
`Adrenosterone
`
`(3-117
`
`B-21!48
`
`2-180
`
`13-135
`
`0-131
`
`91-21160
`
`I
`
`13.211143
`
`0.211151 -
`
`0-111
`
`B-21!48
`
`0-121
`
`(39211151.
`
`3-166
`
`9-211143
`
`191-151
`
`1-111
`
`A-103
`
`H-21!60_
`
`B-2‘H48
`
`-
`
`1992-1145--
`
`'
`
`.
`
`-
`
`-
`
`-
`
`-
`
`-
`
`-
`
`'
`
`B-BOMQ
`
`-
`
`11360191-
`
`B-60!49
`
`_
`
`I
`
`B-BO!49
`
`960152
`
`B-60!49
`
`i
`
`—
`
`1160161" '_
`
`13-60149
`
`A-BOMS
`
`Nprenolol
`
`0-431
`
`D-21354
`
`D—60!55
`
`0-9056
`
`21
`
`AstraZeneca Exhibit 2044 p. 27
`
`

`

`ALPHABETICAL PRODUCT LISTING
`
`I
`
`PI'OdllCt
`
`21-Day Release
`Calming:
`l’rlcu Schedule!
`Numher Page Number
`
`60-Day Release
`Catalog Price Schedule!
`Number Page Number
`
`90-Day Release
`Culalug Price Schedule!
`Number Page Numhur
`
`
`
`
`.
`
`-
`
`.
`
`_
`
`I
`
`-
`
`_
`
`.
`
`5
`
`'
`
`B-21H48
`
`SA- 104
`
`B-SOMQ
`
`13-21148
`A«21!45
`
`SB- 167
`86-118
`
`8430149
`A-BOMG
`
`13—21148
`13-21148
`
`80-181
`SA— 105
`
`13-60149
`13-60149
`
`.A-211'45
`
`SIX-106
`
`131-60146
`
`13-21148
`B—21f43
`
`SA- 107
`SA— 108
`
`8-60149
`8-60149
`
`8-2-1148
`(3—21151
`6-21146
`B-21/48
`
`0-211’51
`3-21148
`
`[31-21154
`3-21148
`”114.1145.
`13-21148
`' 3:21:48
`13-21151
`
`83-111
`80-125
`SA-109
`SA- 1 1 2
`
`SC-451
`SB-112
`
`88-113
`88-114
`80-107
`SA-131
`5311-121
`SA- 141
`
`8-60149
`060152
`360.149
`3-60.149
`
`13-6052
`8-60149
`
`D-60l55
`13-60149
`111-60146
`53-60149
`660149
`060152
`
`-.p+21154_
`13—21143
`
`I
`
`811-101
`SK-114
`
`060155
`13-60149
`
`_'
`
`.
`
`-- 3-21/48- Ski-115
`13-21151
`80-461
`
`13—60149”
`060152
`
`11-21145
`11-21145
`
`SF- 111
`SF— 161
`
`A-60I46
`111-60146
`
`B-QDI50
`
`”13—90150
`A-901'4?
`
`3690150-
`8-9060
`
`111-90147
`
`8-9050
`3-90150
`
`13-90156
`
`B—QOISO
`090153
`3-90150
`B-QOISO
`
`13—9053
`8-90.60
`
`D-QOISB
`3-90150
`1149014.?
`61-90150
`3490150
`13-90153
`
`0-90156
`3-90150
`
`13-90150
`090153
`
`11-90147
`11-90147
`
`Aminoglutethimide
`
`0-21154
`
`86-281
`
`0-60155
`
`Althiazide
`
`' Arfia‘dtfidine '
`Amcifionide
`
`II
`
`'
`Amiioride
`Amineacetonitrile
`
`d—AmihOacetdphenone
`
`m-Aminoacetophenone
`p-Amihoéceto‘phehoné
`
`.
`
`.B-Aminopenicillanic-Acid
`Aminophylline I
`Aminppynné '
`Amiodaro-ne-
`
`.Am'itfiptyi_i11e '
`Amo11icillin
`I
`
`,
`
`I
`
`_
`
`'
`
`_
`
`_.=_-Am_pihotéri¢ih a:
`Amp-11211116-
`_.'-Ar_"r_1ri'nc51_ne f;
`'
`_
`Ahdrostenediol
`136666.066 SubstancesPegeal
`Andros‘enedlone(Se—ew'krfiswééaéaiai.
`Sa-Androsterone
`
`-- 515Androsterone -
`I Anieedemine
`
`':.A_n_'i'sgd_1nje.;..x
`I Ahtazoline
`
`.-_. .Arachididfigid
`Arachaéonic Acid
`
`.'
`
`-
`
`.
`
`--
`
`-_
`
`if
`
`I
`
`_
`
`_
`
`'
`I
`
`_
`
`22
`
`AstraZeneca Exhibit 2044 p. 28
`
`

`

`-
`
`ALPHABETICAL PRODUCT LISTING—
`
`Dosefl’rice Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release
`CIIIIIIIIg l’IiL-I:
`SCIIC‘UIIIU
`NIIIIIhI-I Pilfll: Number
`
`60-Day Release
`CIImII'gI [-‘riu Schulnlm
`VIIIIIhL-r
`l'agu.
`\Itluhu
`
`90-Day Release
`( Iaglllln I‘rIcu. SclIetlIIlu'
`Number Page
`\uIIIlIL-I
`
`Arecoline
`
`-
`
`0-2051
`
`c-60I52
`
`-
`
`(3-90x53
`
`.
`
`'
`
`-
`
`.
`
`'
`
`3F;;;§j__'.p’-Arginine
`._ L-Arginine
`449
`:I-[l-Asparagine
`i"?35-":.-.:;L'-;I49_;saragine
`mil-JI-AsparticAcid
`ii;3.~_::.'_-'L-A'spart'ic Acid
`I. Aspirin
`;:-33'tenolol
`Atropine
`:‘.3:§--E-Afr'opine Methyl Bromide
`__ B—Azaadenine
`
`fig-:‘IS-Azacytidine
`“ s-Azaconsine
`
`-
`
`-
`-
`-
`
`'
`
`-
`
`-
`
`-.
`
`I
`
`'
`
`_
`
`-
`--
`-'
`
`-
`
`'3 f [3-21343-
`-
`c-21I51
`9-2-19
`C-élf51: "-
`(3-2051 -i:-=
`..
`0-2051
`-
`0-2051 -
`-
`0-2051
`-
`3-2043.
`0-2451
`c-2'1I51 _
`3-2048
`
`”-'.'-_3.'-_é'0I495--2390:59’:
`(3-6062 I
`I
`c-9053
`Haw --
`;: "-'
`H9962
`0-6052"
`U -
`IC—90f53
`”03052)
`._
`c9033
`05032
`I
`I.
`0-9063
`0-6052”-
`9490353
`c-eorsz
`090453
`390149
`'.-'.3-_93!50'._
`Isl-30:52
`0-9053
`33052
`(5490/53.
`3-60I49
`3-90I50
`
`'
`
`_
`
`' 4'
`-
`
`'-
`.
`-
`
`..
`
`-
`
`_
`
`'
`
`'
`
`-
`-
`
`-
`
`III-21:45
`c-2051
`
`C-21I‘51
`
`-
`-
`
`-
`
`A-BOMS-
`0-6052 I
`
`.
`
`C-60f52 _
`
`_
`
`-
`-
`
`-
`
`A-90I4?
`0-9033
`
`6-9053
`
`
`
`8:Azaguanine
`
`B-Azahypoxanthine
`
`__
`
`0-:-Azathymine
`.1:;'_.'AzauraCIl
`6Azauracil
`figmundm
`
`Bacitracin
`
`E‘Eclofen
`Beclomethasone
`
`-
`
`-
`-
`-
`
`-
`
`_
`-
`
`N
`
`'
`
`.
`
`.
`
`(3-2051
`
`3-2043
`
`3-2048
`3-2043;
`C-21f51
`3-2949
`
`B-21f48
`
`-
`
`3.421345
`0-2154: I
`
`0:21:54
`C-21I’51-
`
`-
`
`-
`
`-
`_-
`-
`-
`
`-
`
`-
`
`-
`
`0-6052
`
`-
`
`090453
`
`330x49
`
`3-60I49
`3-00149
`C-60!52
`3-3039
`
`-
`
`-
`__-_ ._
`-
`-_
`
`-'
`
`3-9050
`
`3-9030
`3-9050-
`0-9053
`3-9350
`
`B-QOISD
`
`B-GOMQ
`
`A—GOMS
`III-BOISE
`
`93-30155
`0-6053
`
`'
`
`I
`
`-
`
`.-
`-
`
`_-
`-
`
`'
`
`_ 3-903?
`D-90f56
`
`--
`
`'
`
`3-9059
`0-9053
`
`23
`
`AstraZeneca Exhibit 2044 p. 29
`
`

`

`ALPHABETICAL PRODUCT LISTING
`
`I
`
`Dosefl’rice Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`.
`_
`PTOdIILt
`
`(‘nlnh‘rg Price Schedule!
`Number Page Number
`
`Catalog Price Srltedulef
`Number Page Number
`
`l‘ricv Schedule!
`Catalog:
`\lumher Page Numher
`
`21-Day Release
`
`60-Day Release
`
`90-Day Release
`
`Belametl'lasone
`
`(3-191
`
`b21763
`
`86-191
`
`L-607'64
`
`NG—191
`
`L-90f65
`
`Boldine
`
`K-120
`
`0-21751
`
`SK-120
`
`0-60752
`
`NK—120
`
`0-90.353
`
`B-Bromoadenosine 3':5‘ Cyciic Monuphosphate
`
`N-221
`
`M21766
`
`SN-221
`
`M-SO-G?
`
`NN-221
`
`571-90768
`
`Bromocriptirle Mesylale
`
`0-231
`
`E-217‘5?
`
`30-231
`
`E-60758
`
`N0-231
`
`590759
`
`5—Br0m0-2'-Deoxyuridine (BrDUl
`
`N-231
`
`3-21748
`
`SN-231
`
`B-BUMQ
`
`NN-231
`
`B-QOISO
`
`Brucine
`
`-
`
`Busulfan [MyleranJI
`
`K-1 22
`
`0-21751
`
`SK-122
`
`0-60752
`
`NK-122
`
`0-90753
`
`2-1 30
`
`3-21748
`
`32-1 30
`
`8-60749
`
`N2- 130
`
`8-90750
`
`Caffeine
`
`'
`
`0—191
`
`0-217'51
`
`80-191
`
`0-60152
`
`NC-191
`
`0-90753
`
`Calycanlhine
`_ Camptolfiecin
`
`'
`
`Caplopril
`
`'
`
`'Carbamazepine
`
`Carbinoxamine
`
`K423
`0-115
`
`8-21748
`SK-123
`E-21757. 30-116
`
`8450749
`560758
`
`NK-123
`N0-116
`
`3-90750
`590759 .
`
`""
`
`0-117
`
`3-21748
`
`30-117
`
`B-607‘49
`
`N041?
`
`8—90750
`
`0-113
`
`0-21751
`
`80-113
`
`0-60152
`
`N0-113
`
`0-90753
`
`0-471
`
`0-21751
`
`30-471
`
`0-60752
`
`NC-471
`
`0-90753
`
`NV-271
`
`0-90!53
`
`090753
`
`3-170
`
`A-21745
`
`88-170
`
`A-SOMG
`
`NB-170
`
`A—QOM?
`
`8-171
`
`ail-21745
`
`38-171
`
`71-60746
`
`NIB—171
`
`A-90747'
`
`3-172
`
`A-21145
`
`33-172
`
`A-BOMS
`
`NIB-172
`
`71-90747
`
`-
`
`-
`
`-_B-173
`
`A—21f453
`
`33-173
`
`A-eome
`
`NB-173 - A-90747’
`
`8-1 74
`8-175
`
`71-21745
`A-21745
`
`38-1 74
`SB-175
`
`71-60746
`A—60746
`
`NB-174
`NB-175
`
`71-9074?
`71-90747
`
`3-176
`
`A-21745
`
`88-176
`
`A-EDMB
`
`NB-176
`
`A—90747
`
`3-177
`
`A-21f45
`
`SB-177
`
`14-60746
`
`NB-177
`
`'A—90747
`
`'
`
`.
`
`.
`
`I
`
`3-178
`
`A-21745
`
`83-178
`
`71-60746
`
`NIB-178
`
`A-90747
`
`CentrophenOxine (Meclofenoxate)
`
`0-115
`
`0-21751
`
`80-115
`
`0-60752
`
`NC- 11 5
`
`Cephalexin
`
`3-118
`
`B-21i‘48
`
`88-118
`
`8-60749
`
`NB-118
`
`8-90750
`
`24
`
`AstraZeneca Exhibit 2044 p. 30
`
`V—271
`
`0-21751
`
`SV—271
`
`0-60.62
`
`V—215
`
`0-21751
`
`SV—21 5
`
`0-60752
`
`NV—215
`
`0-90753
`
`-
`
`'
`
`.
`
`We can custom make any dose and any release time. {PLEASE INQUIRE}
`
`IDL-Carnitiné
`
`Ill-Carotene
`
`. TCasodeX- (mama-sag}
`
`Cefadroxil
`
`'Cefamandole.
`
`.
`
`Cefazolin
`
`-: Cemetazbie'
`
`-'
`
`_.
`
`I
`
`-
`
`Cefoperazone
`Celcitaxifne -
`
`Cefoxitin
`
`Cefsulodin
`
`Ceftriaxone
`
`

`

`_,
`
`- ALPHABETICAL PRODUCT LISTING—
`
`DoselPrice Schedules For Matching Placebo Pellets Appear On Pages 17-19
`
`Pl'UdUCt
`
`Cephaloglycin
`
`gCephalothm
`Cephapirin
`
`Chloramphenicol
`"'Chloramphenicol Base
`
`Chlorcyclizine
`femurmadinone Acetate
`”Chloroquine
`:ibhlorothiazide
`Chlorotrianisene
`
`Egbhlorpheniramine
`
`Chlorpromazine
`
`”lgghlonhalidone
`Chlorzoxazone
`
`21--Day Release
`
`60-Day Release
`
`90--Day Release
`
`( Mlllll I'riL'L' SchLdulL‘r
`Numlnr Page Numher
`
`Lalnlug I’IiL'L SchululL'.
`Numher P1113 Number
`
`(‘ 31:11:11; PI’it‘t Suiludllluf
`Number Page Numhel
`
`8-119
`
`D-211'54
`
`D-6055
`
`[118-119 D90156
`
`--
`
`'
`
`1
`
`'.
`
`’-'B:-il1120.'"r-'3.'B21140 ”IE-601492313113120
`3-121
`I 3-21148
`-
`13-60149
`NB-121
`
`13-90150
`
`X-13‘l
`13-1 23' .
`
`C-211'51
`'C'42-1l'51f'.
`
`-
`
`(3-145
`3-21148
`9-221 ' 0-21-1215
`1-112
`0-21151
`0-155
`0-211'51'
`0-201
`0-21151
`
`-
`
`13-124
`
`0-21151
`
`0-241
`
`021151
`
`0-115
`C-185
`
`13-21148
`021151
`
`'I
`
`'
`
`-
`
`-
`
`if
`
`_
`
`-
`
`'
`
`-
`
`-
`
`-
`
`'
`
`C-BOISZ
`NX-131
`090353
`050152 11113123990153
`
`8-60149
`NC-145
`13-90150
`11-50145;:'_-111é_-'22_1:;=I--.- A9014?
`13-50152
`111-112
`090153
`13-00152} 110155 090153
`0-00152
`1115-201
`0-90153
`
`13-50152»
`
`113-124;.{0-90153:
`
`(3-6015?!
`
`NC-241
`
`0-90153
`
`13-50149
`060152
`
`13-50149
`060152
`
`N0-1“?5_- 0100159
`MCI-185
`13-90153
`
`110-312
`110-154
`
`3.90150
`00053
`
`
`
`1: gim'etidine
`Cinchonidine
`
`:0‘1hnarizine
`
`0Iemasune
`11- |em1zole
`
`Clenbuterol
`
`0111100101
`
`Clomiphene Citrate
`yflgs'mipramine
`
`Clonidine
`
`jiéébamide
`
`0-372
`13-154
`
`3-125
`
`0-120
`0-110
`
`51-21148
`0-21151
`
`0-21151
`
`53-21140
`0-2115'1
`
`0-110
`
`H-21150
`
`0-104
`
`P-211
`0-103
`
`0-21151
`
`13-21140
`0-21151
`
`0-251
`
`13—21140
`
`0-105
`
`13-21148
`
`-
`-
`
`—
`
`-
`-
`
`-
`
`-
`
`-
`-
`
`-
`
`—
`
`0-50152 _
`
`110-125
`
`0-0015-3-
`
`53-60149
`0-00152
`
`110-120
`110-119
`
`0-9050
`0-90153'
`
`H-501'B1
`
`110-110
`
`H-90152
`
`0-50152
`
`110-104 .. 0-00153
`
`13-50149
`000152
`
`NP-211
`110-103
`
`13-90150
`00053
`
`51-50149
`
`110-251
`
`B00150
`
`13-00149
`
`110-105.-
`
`133—90150-
`
`Clotrimazole
`
`5-125
`
`13-21143
`
`-
`
`13-50149
`
`110-125
`
`13-00150
`
`25
`
`AstraZeneca Exhibit 2044 p. 31
`
`

`

`ALPHABETICAL PRODUCT LISTING
`
`— D
`
`oselPrice Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`PI'OdllCt
`
`21-Day Release
`Calming Prin- Schedule!
`Numhur Page
`N11:11l.11.-r
`
`60-Day Release
`(_":11:1ll'1gl"1-iue Schedule!
`Number Page Numlm-
`
`90-Day Release
`Calulug Price 5111011111121“
`Number Page Number
`
`Cloxacillin
`
`13-21149
`
`SB-12‘1’
`
`860149
`
`'
`
`-
`
`Colchlcme
`
`_-
`
`'
`
`:_-
`
`Cortexoione
`
`IvCortlexfilioiig'Acetate
`
`-
`
`Corticosterone
`
`11336015651510.11-6'21-Acetate
`001030113
`
`I
`
`Cortisohe Acet-ale
`
`{-)Cotinine
`
`'- Coumarin (1.2 Banzopyrone}
`I Cromolyn
`
`' Crotaline
`
`Cyclizine
`
`_,5 .
`
`11-2-1145"? 4313-155
`
`A-60146 .
`
`I
`
`-
`
`__ '
`
`_
`
`1321148
`
`313601
`
`1360149
`
`13-21148
`
`36-311
`
`13-60149
`
`11-21145
`
`36-111
`
`101-60146
`
`11-21145
`8-21148
`
`313-171
`313-121
`
`11-60146
`B60149
`
`13-21148
`
`33-181
`
`B60149
`
`11-21145
`
`311- 124
`
`131-60146
`
`C-21151
`6-21148
`
`80-112
`313-195
`
`6-60152
`B60149
`
`13-21154
`
`311-125
`
`1360155
`
`11-21145
`
`313-108
`
`A-601’46
`
`191-60146
`
`1360150
`
`1111-19014?"-
`
`13-90150
`
`13-90150
`
`11-90147
`
`11-90141
`53-90150
`
`13-90150
`
`11-90147
`
`0-90153
`13-90150
`
`13-90156
`
`11-90141
`
`11-90147
`
`
`
`Cyclophosphamide (Cytoxan)
`
`11-21145
`
`32- 150
`
`D-Cycloserine
`
`.Cymarin _
`
`.
`
`Cyproheptadine
`
`3-21148
`
`88-128
`
`8-60149
`
`13-21154
`
`313-362
`
`060155
`
`11-21145
`
`313-481
`
`11-60146
`
`8-90150
`
`13-90156
`
`11-90147
`
`E90159
`
`13-90153
`13-90153 _
`
`13-90156
`
`13-90153
`
`0-90156
`
`E60159
`
`13-90153
`
`11-90155
`
`Cypr'oterone Acetate
`
`5-2115?
`
`313-114
`
`E60158
`
`D-Cysieine
`'_. L-Cyste‘ihe'
`
`0611511116
`
`-
`
`13-21151
`13-21151
`
`30-201
`312-211
`
`13-60152
`1360152
`
`13-21154
`
`30-221
`
`060155
`
`L-Cystine.
`
`'
`
`'
`
`-
`
`6-21151
`
`30-231
`
`1360152
`
`Cytarabine {6111651116 Arabinnside]
`
`D-211‘54
`
`82- 160
`
`13-60155
`
`Gytisi'ne
`
`Cytosine
`
`Danazol
`
`-
`
`'
`
`E-21157
`
`311- 126
`
`E60156
`
`13-21151
`
`311-241
`
`13-60152
`
`13-21154
`
`319-251
`
`1360155
`
`Daunorubucine
`
`H-211‘60
`
`82- 170
`
`H6016?
`
`H-90162
`
`26
`
`ll
`
`AstraZeneca Exhibit 2044 p. 32
`
`

`

`'r-
`
`ALPHABETICAL PRODUCT LISTING—
`
`Dosefl’rice Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`rase
`
`21-Day Release
`L‘ulnlug Price Schedule!
`\‘urnbcr Page Number
`
`60-Day Release
`Catalog l’rice {‘icllcrlulclr
`Number Page Numhur
`
`90-Day Release
`{'alalug Price Schedule!
`Number Page Number
`
`”50
`
`3-Deazauracil
`
`3-212'48
`
`B-BUMQ
`
`3-9050
`
`1150
`
`1350
`1:47
`H47-
`U50
`I3'50
`I’47
`1:53
`l350
`1156
`
`”’47
`
`#4?
`I550
`
`I Decamethoniurn Bromide
`
`Luriévillefthamine Masylate
`hill-Dehydrocholesterol
`_,§:'f‘b§hydr.ocholic Acid
`I‘m-ll-[Jehydroepiandrosterone (DHEA)
`fir???fiEhydroepiandrostefone Acetate
`Dehydroepiandrosterone Sulfate
`if};'16—'Dehydropregnenolme
`16—Dehydropregnenolone Acetate
`_‘-,1.6-Dehydroprogesterone
`
`Demeclocycline
`
`_-Deoxycholic Acid
`Deoxycorticosteronemoc;
`
`"
`
`-'
`
`I
`
`'
`
`-
`
`B-2ll48 I
`
`.07217547
`c-21r51
`_ 0-2151:
`B-ZMB
`3-21-148-
`D--21f54
`'B.-21f48
`B-21l48
`B-21I48 -
`
`.'
`
`-
`
`B-21a’48
`
`c.2151
`B-21f48
`
`A—2'1l45
`
`_
`
`BI-ESDMQ --
`
`- 8-9050
`
`-
`
`.
`
`05015531:
`c-aoisz
`. " -eé$fi£'5"2-'i""
`B-GOMQ I
`8-46-0349-
`D-60l55
`B—‘S'Ol49-I
`B-GUMQ
`B-60!49_
`
`I
`
`=
`
`'
`
`'.
`
`_
`
`I 13902561
`090155
`I
`c9053
`B-QOISll -
`890150?
`D—QOISB
`390150
`B—QOISO
`9:90:50]
`
`B-QOISO
`
`'
`
`'_C&9‘0f53-
`B-QfllSO I
`
`_ #90347.‘
`
`B-BOMQ
`
`0—6052
`B-60l49
`
`#60145 I
`
`C-QOI53
`
`Déoxyconicosterone Acetatewocm
`
`Desipramine
`
`pflésoximemsone
`I IDexamethasone
`.:-._§'}-'f_Dexamethasone 21-Acetale
`
`Dexamethasone 21-Phosphate
`
`Dlaveridine
`
`ff- Diclofenac
`
`Dicioxacillin
`
`Dieriest'rol
`
`Dienestrol Diacetate
`
`'_
`
`3-21348
`
`0-2154
`0-21.64
`0-2154 '
`
`D-21IS4
`
`0-21r54
`
`B-21l48
`
`321,143
`
`0—2151
`
`C-21f51
`
`3-60149
`
`0-6055.
`[1-60)f55
`0-6.0{55
`
`D-60l55
`
`0-6065"
`
`.
`
`_
`
`B-60f49 .
`
`_
`
`B-60f49
`
`. 0-6.0!52
`
`8-6062
`
`-
`
`'
`
`.
`
`B-QOISU
`
`.D—‘aorss
`0-90.55
`:Dféokse
`
`0-905?)
`
`-_ 0490156}
`
`3599559
`
`3-9050
`
`”©9053.
`
`AstraZeneca Exhibit 2044 p. 33
`
`”56
`
`M7
`
`#59
`If53
`”'53
`
`”56
`
`#53
`
`:59
`
`II53
`
`”56
`
`II132
`
`

`

`ALPHABETICAL PRODUCT LISTING 1
`
`I
`
`Product
`
`21-Day Release
`(fuming l’riee Schedule!
`Number Page
`.‘N'nmher
`
`60-Day Release
`{.Talalug l'rice Sullt‘tiillu."
`Number Page Number
`
`90-Day Release
`(Imalng Price. Schedule-1'
`Number Page Number
`
`Dielhylstilbestrolmes;
`
`E-151
`
`13-21149
`
`95-151
`
`050149
`
`1115-151
`
`990150
`
`0191101511
`‘Digoxin
`
`;515yd_r55;g55555
`
`'
`
`..
`
`'_
`
`= 0-195. '. 213-24148 -
`0-2?1'
`13-21149
`
`' 80-195
`30-271
`
`13-50149 00-195 59-90150",-
`13-50149
`00-271
`13-90150
`
`__K-12'? 1
`
`521157 810127 15-50153
`
`-NK-.12?
`
`95-90159"
`
`I
`
`'
`
`50-Dihydrolestoslerone
`{See Conunflea Suwanee: Page 3)
`
`Specia